AA
ALNA

ALPS Advisors’s Allena Pharmaceuticals ALNA Stock Holding History

ALPS Advisors’s Portfolio ALNA Stock Details ALNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-36,722
Closed -$394K – 969
2018
Q3 		$394K Buy
36,722
+6,686
+22% +$73.5K ﹤0.01% 880
2018
Q2 		$391K Buy
+30,036
New +$433K ﹤0.01% 788

Other funds holding ALNA

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
DVC
Deer VII & Co Larchmont, New York $317M AUM 30.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

ALPS Advisors's ALNA Position: Q4 2018 in Review

ALPS Advisors sold out of Allena Pharmaceuticals (ALNA) in Q4 2018, closing a stake of 36,722 shares — an estimated $394K sold.

ALPS Advisors first reported a position in ALNA in Q2 2018 and held it in 2 quarters. The position peaked at $394K in Q3 2018. 49 funds tracked by Wall St. Rank hold ALNA as of Q4 2018.

  • ALPS Advisors reported no remaining Allena Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • ALPS Advisors sold 36,722 Allena Pharmaceuticals shares in Q4 2018, an estimated $394K.
  • ALPS Advisors first reported a position in Allena Pharmaceuticals in Q2 2018 and held it in 2 quarters.
  • ALPS Advisors's Allena Pharmaceuticals position peaked at $394K in Q3 2018.
  • 49 funds tracked by Wall St. Rank held Allena Pharmaceuticals as of Q4 2018.

Based on ALPS Advisors's 13F filing for Q4 2018, filed 4 Feb 2019.